- Home
- AIFE vs CHRS Comparison
AIFE vs CHRS Comparison
Compare AIFE & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFE
- CHRS
- Stock Information
- Founded
- AIFE 2024
- CHRS 2010
- Country
- AIFE United States
- CHRS United States
- Employees
- AIFE N/A
- CHRS N/A
- Industry
- AIFE
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AIFE
- CHRS Health Care
- Exchange
- AIFE NYSE
- CHRS Nasdaq
- Market Cap
- AIFE 111.4M
- CHRS 112.5M
- IPO Year
- AIFE N/A
- CHRS 2014
- Fundamental
- Price
- AIFE $10.10
- CHRS $0.97
- Analyst Decision
- AIFE
- CHRS Strong Buy
- Analyst Count
- AIFE 0
- CHRS 4
- Target Price
- AIFE N/A
- CHRS $5.26
- AVG Volume (30 Days)
- AIFE 14.5K
- CHRS 1.7M
- Earning Date
- AIFE 01-01-0001
- CHRS 05-12-2025
- Dividend Yield
- AIFE N/A
- CHRS N/A
- EPS Growth
- AIFE N/A
- CHRS N/A
- EPS
- AIFE N/A
- CHRS 0.25
- Revenue
- AIFE N/A
- CHRS $266,959,999.00
- Revenue This Year
- AIFE N/A
- CHRS N/A
- Revenue Next Year
- AIFE N/A
- CHRS $9.02
- P/E Ratio
- AIFE N/A
- CHRS $3.90
- Revenue Growth
- AIFE N/A
- CHRS 3.78
- 52 Week Low
- AIFE $9.89
- CHRS $0.66
- 52 Week High
- AIFE $10.13
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- AIFE N/A
- CHRS 48.50
- Support Level
- AIFE N/A
- CHRS $0.92
- Resistance Level
- AIFE N/A
- CHRS $1.12
- Average True Range (ATR)
- AIFE 0.00
- CHRS 0.07
- MACD
- AIFE 0.00
- CHRS -0.01
- Stochastic Oscillator
- AIFE 0.00
- CHRS 21.28
About AIFE AIFEEX NEXUS ACQUISITION CORPO
Aifeex Nexus Acquisition Corp is a blank check company.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.